The blood concentration and organ distribution of haloperidol at therapeutic and toxic doses in severe fatty liver disease

Legal Medicine

Volumn 14, Issue 3, 2012, Pages 147-153

  Ikemura, Mayumi ^a   Nakagawa, Yasuhisa ^a   Shinone, Kotaro ^a   Inoue, Hiromasa ^a   Nata, Masayuki ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Hypoalbuminemia; Intoxication; Malnutrition; Pharmacokinetics; Portal vein blood flow

Indexed keywords

HALOPERIDOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FATTY LIVER; MALE; NONHUMAN; ORGAN DISTRIBUTION; PORTAL VEIN BLOOD FLOW; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; FATTY LIVER; HALOPERIDOL; MALE; PORTAL VEIN; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX;

EID: 84858332191     PISSN: 13446223     EISSN: 18734162     Source Type: Journal    
DOI: 10.1016/j.legalmed.2012.01.012     Document Type: Article

References (39)

1. Kudo S., Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999, 37:435-456.
2. Schreinzer D., Frey R., Stimpfl T., Vycudilik W., Berzlanovich A., Kasper S. Different fatal toxicity of neuroleptics identified by autopsy. Eur Neuropsychopharmacol 2001, 11:117-124.
3. Kane J.M. The current status of neuroleptic therapy. J Clin Psychiatry 1989, 50:322-328.
4. Wilkinson G.R., Shand D.G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975, 18:377-390.
5. Nies A.S., Shand D.G., Wilkinson G.R. Altered hepatic blood flow and drug disposition. Clin Pharmacokinet 1976, 1:135-155.
6. Blaschke T.F. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 1977, 2:32-44.
7. Yoshida I., Sakaguchi Y., Matsuishi T., et al. Acute accidental overdosage of haloperidol in children. Acta Paediatr 1993, 82:877-880.
8. Johnson G.R. High haloperidol concentrations in a traffic suicide. J Forensic Sci 1988, 33:823-825.
9. Korpi E.R., Kleinman J.E., Costakos D.T., Linnoila M., Wyatt R.J. Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 1984, 11:259-269.
10. Bae S.K., Lee D.Y., Lee A.K., et al. Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. J Pharm Sci 2004, 93:2388-2398.
11. Lee A.K., Ahn C.Y., Kim E.J., et al. Effects of cysteine on the pharmacokinetics of itraconazole in rats with protein-calorie malnutrition. Biopharm Drug Dispos 2003, 24:63-70.
12. Pfaender M., Casetti P.G., Azzolini M., Baldi M.L., Valli A. Successful treatment of a massive atenolol and nifedipine overdose with CVVHDF. Minerva Anestesiol 2008, 74:97-100.
13. Hanagama M., Inoue H., Kamiya M., Shinone K., Nata M. Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver. Leg Med 2008, 10:177-184.
14. Inoue H., Sameshima N., Ishida T., Tsuji A., Kudo K., Ikeda N. Vulnerability of experimentally induced fatty liver to heat stress in rats. J Gastroenterol 2006, 41(1):55-61.
15. Inoue H., Tsuji A., Kudo K., Ikeda N. Pulmonary fat embolism induced by exposure to high ambient temperature in rats with a fatty liver. Int J Legal Med 2005, 119:275-279.
16. Verbeeck R.K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008, 64:1147-1161.
17. Le Couteur D.G., Fraser R., Hilmer S., Rivory L.P., McLean A.J. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005, 44:187-200.
18. Niemegeers C.J., Janssen P.A. Bromoperidol, a new potent neuroleptic of the butyrophenone series. Comparative pharmacology of bromoperidol and haloperidol. Arzneimittelforschung 1974, 24:45-52.
19. Zipprich A., Steudel N., Behrmann C., et al. Functional significance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology 2003, 37:385-392.
20. Francque S., Wamutu S., Chatterjee S., et al. Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. Liver Int 2009, 30:365-375.
21. Fernandez-Repollet E., Tapia E., Martinez-Maldonado M. Effects of angiotensin-converting enzyme inhibition on altered renal hemodynamics induced by low protein diet in the rat. J Clin Invest 1987, 80:1045-1049.
22. Gepdiremen A., Aydin N., Halici Z., et al. Chronic treatment of haloperidol causes vasoconstriction on basilar arteries of rats, dose dependently. Pharmacol Res 2004, 50:569-574.
23. Blessing W.W. Clozapine and olanzapine, but not haloperidol, reverse cold-induced and lipopolysaccharide-induced cutaneous vasoconstriction. Psychopharmacology 2004, 175:487-493.
24. Blessing W.W. Clozapine increases cutaneous blood flow and reduces sympathetic cutaneous vasomotor alerting responses (SCVARs) in rats: comparison with effects of haloperidol. Psychopharmacology 2005, 181:518-528.
25. Procyshyn R.M., Tsai G., Wasan K.M. The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. Eur Neuropsychopharmacol 2003, 13:33-37.
26. Gaulin B.D., Markowitz J.S., Caley C.F., Nesbitt L.A., Dufresne R.L. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999, 156:1270-1272.
27. Rice E., Makuku S. Role of cholesterol in the distribution of haloperidol and trifluoperazine in blood and plasma. Biochem Pharmacol 1981, 30:951-957.
28. Vasconcelos S.M., Pereira R.F., Alves R.S., et al. Effects of ethanol and haloperidol on plasma levels of hepatic enzymes, lipid profile, and apolipoprotein in rats. Biochem Cell Biol 2004, 82:315-320.
29. Procyshyn R.M., Ho T., Wasan K.M. The effects of competitive displacement on haloperidol's plasma distribution in normolipidemic and hyperlipidemic plasma. Drug Dev Ind Pharm 2005, 31:901-905.
30. Wilkinson G.R. Clearance approaches in pharmacology. Pharmacol Rev 1987, 39:1-47.
31. Higashi Y., Kitahara M., Fujii Y. Simultaneous analysis of haloperidol, its three metabolites and two other butyrophenone-type neuroleptics by high performance liquid chromatography with dual ultraviolet detection. Biomed Chromatogr 2006, 20:166-172.
32. Bock E., Weeke B., Rafaelsen O.J. Serum proteins in acutely psychotic patients. J Psychiatr Res 1971, 9:1-9.
33. Nemeroff C.B., Krishnan K.R., Blazer D.G., Knight D.L., Benjamin D., Meyerson L.R. Elevated plasma concentrations of alpha 1-acid glycoprotein, a putative endogenous inhibitor of the tritiated imipramine binding site, in depressed patients. Arch Gen Psychiatry 1990, 47:337-340.
34. Kehoe W.A., Kwentus J.A., Sheffel W.B., Harralson A.F. Increased alpha-1-acid glycoprotein in depression lowers free fraction of imipramine. Biol Psychiatry 1991, 29:489-493.
35. Jann M.W., Crabtree B.L., Pitts W.M., Lam Y.W., Carter J.G. Plasma alpha-one acid glycoprotein and haloperidol concentrations in schizophrenic patients. Neuropsychobiology 1997, 36:32-36.
36. Forsman A., Ohman R. Studies on serum protein binding of haloperidol. Curr Ther Res Clin Exp 1977, 21:245-255.
37. Seakins A., Waterlow J.C. Effect of a low-protein diet on the incorporation of amino acids into rat serum lipoproteins. Biochem J 1972, 129:793-795.
38. Laduron P. Limiting factors in the antagonism of neuroleptics on dopamine-sensitive adenylate cyclase. J Pharm Pharmacol 1976, 28:250-251.
39. Levine B.S., Wu S.C., Goldberger B.A., Caplan Y.H. Two fatalities involving haloperidol. J Anal Toxicol 1991, 15:282-284.